首页 BridgeBio Pharma, Inc.(usBBIO)-基本信息

BridgeBio Pharma, Inc.(usBBIO)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:55.87

最高价:56.12

成交量:507631.0

昨收价:54.95

最低价:53.99

最新价:55.12

行情图标
概要信息

英文名称:BridgeBio Pharma, Inc.


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 持股信息
  • 领导人信息

BridgeBio Pharma公司在2015年成立,以识别和推进变革性药物,以治疗患有孟德尔疾病(Mendelian diseases)的患者,这些疾病是由单一基因缺陷引起的疾病,以及具有明确遗传驱动因素的癌症。BridgeBio超过15个开发项目的管道包括从早期发现到后期开发的候选产品。BridgeBio Pharma目前有4个临床阶段产品,其中两个候选产品处于 III 期临床试验阶段,一个处于II/III 期临床试验阶段,另一个处于 II 期临床试验阶段。BridgeBio Pharma专注于遗传性疾病,因为它们存在于高度未满足的需求和易处理的生物学的交叉点。BridgeBio Pharma的方法是将在学术实验室和领先医疗机构中首创的研究转化为公司希望最终将惠及患者的产品。通过科学进步的融合,公司能够实现这一机会,包括: i)随着更具成本效益的基因组和外显子组测序的出现,确定疾病的遗传基础; (ii)分子生物学的进展; (iii)纵向数据的发展和成熟以及能够将基因与疾病联系起来的回顾性研究。BridgeBio Pharma, Inc.(BBIO)融资百科:2017年9月13日,专注于遗传性疾病的生物技术公司BridgeBio Pharma在C轮融资中筹集了1.35亿美元,C轮融资由 Viking Global Investors 和 KKR 领投,Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital 和 Janus Funds 跟投。2019年1月23日,专注于遗传病的临床阶段生物制药公司BridgeBio Pharma今天宣布,公司在D轮融资中获得了2.992亿美元的新融资。D轮融资由现有投资者KKR和Viking Global Investors共同领导。 其他现有投资者包括Perceptive Advisors,AIG,Aisling Capital,Cormorant Capital和Hercules Capital; 其他新投资者包括红杉资本(Sequoia Capital)和一家蓝筹长期投资者。BridgeBio Pharma, Inc.(BBIO)历史百科: 2018年1月30日,BridgeBio以6500万美元和废止的诺华癌症计划成立QED Therapeutics。 2018年4月5日,BridgeBio Pharma参与对子公司Eidos Therapeutics的6400万美元的B轮投资,该轮由RA Capital Management领导,参投者包括Janus Henderson,Viking Global Investors,Aisling Capital,Perceptive Advisors,Cormorant Asset Management和Amzak Health Investors。 2018年6月11日,BridgeBio Pharma宣布已与Alexion Pharmaceuticals, Inc.达成协议,收购环状吡喃喋呤单磷酸酯(cPMP; ALXN1101),这是一种合成酶辅因子疗法,用于治疗因钼辅助因子缺乏引起的超罕见疾病(MoCD) A型。此外,BridgeBio宣布成立新的子公司Origin Biosciences,其资金充足,可通过潜在的监管审批和商业化支持ALXN1101的临床开发。

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
AMG Funds LLC 10589 0.01% 10589 -- 2019-07-31
Fidelity SelectCo, LLC 81586 0.07% 81586 -- 2019-07-31
Pictet Asset Management (Europe) SA 73861 0.06% 73861 -- 2019-07-31
Vanguard Investments Australia Ltd 41493 0.03% 41493 -- 2019-07-31
Columbia Mgmt Investment Advisers, LLC 25115 0.02% 25115 -- 2019-07-31
JPMorgan Chase Bank 24970 0.02% 24970 -- 2019-07-31
BlackRock Advisors LLC 24479 0.02% 24479 -- 2019-07-31
Janus Capital International Ltd 21977 0.02% 21977 -- 2019-07-31
JP Morgan Asset Management (UK) Ltd 20365 0.02% 20365 -- 2019-07-31
Voya Investments, LLC 20300 0.02% 20300 -- 2019-07-31
GuideStone Capital Management, LLC 11800 0.01% 11800 -- 2019-07-31
FIL Fund Management Limited 11276 0.01% 11276 -- 2019-07-31
Advanced Series Trust 85007 0.07% 85007 -- 2019-07-31
Vanguard Group Inc 87120 0.07% 87120 -- 2019-07-31
Fidelity Management & Research Company 2360900 1.91% 2360900 -- 2019-07-31
Fidelity Management Trust Co 496600 0.40% 496600 -- 2019-07-31
Victory Capital Management Inc. 410640 0.33% 410640 -- 2019-07-31
Franklin Advisers, Inc. 350000 0.28% 350000 -- 2019-07-31
Massachusetts Financial Services Company 345933 0.28% 345933 -- 2019-07-31
J.P. Morgan Investment Management, Inc. 340974 0.28% 340974 -- 2019-07-31
FIL Investment Services (UK) Ltd 9056 0.01% 9056 -- 2019-07-31
Legal & General Investment Management America Inc 56 -- 56 -- 2019-06-30
Vanguard 162 -- 162 -- 2019-06-30
FIL Life Insurance Limited 754 -- 754 -- 2019-06-30
Henderson Management SA 2589 -- 2589 -- 2019-06-30
FIL Limited 4339 -- 4339 -- 2019-06-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity 56900 0.05% 56900 -- 2019-06-30
Victory RS Small Cap Growth Fund 339960 0.28% 339960 -- 2019-06-30
Fidelity Contrafund Commingled Pool 258200 0.21% 258200 -- 2019-06-30
Fidelity Growth Company Commingled Pool 228800 0.19% 228800 -- 2019-06-30
MFS New Discovery Fund 225171 0.18% 225171 -- 2019-06-30
Fidelity Advisor 212100 0.17% 212100 -- 2019-06-30
JPMorgan Small Cap Growth Fund 207012 0.17% 207012 -- 2019-06-30
Franklin Biotechnology Discovery Fund 136000 0.11% 136000 -- 2019-06-30
MFS 119884 0.10% 119884 -- 2019-06-30
JPMorgan US Small Company Fund 73600 0.06% 73600 -- 2019-06-30
Pictet TR - Divers Alpha 71209 0.06% 71209 -- 2019-06-30
Vanguard Small Cap Growth Index Fund 5119 -- 5119 -- 2019-06-30
Janus Henderson Horizon Biotechnology 2589 -- 2589 -- 2019-06-30
Vanguard Instl Total Stock Market Idx Fd 1088 -- 1088 -- 2019-06-30
Vanguard Russell 2000 Index Fund 940 -- 940 -- 2019-06-30
Vanguard Small Cap Value Index Fund 6153 0.01% 6153 -- 2019-06-30
Vanguard Extended Market Index Fund 10436 0.01% 10436 -- 2019-06-30
Victory RS Science and Technology Fund 42750 0.04% 42750 -- 2019-06-30
Vanguard Total Stock Market Index Fund 41493 0.03% 41493 -- 2019-06-30
Multi-Manager Small Cap Equity Strat Fd 25115 0.02% 25115 -- 2019-06-30
BlackRock Event Driven Equity Fund 24479 0.02% 24479 -- 2019-06-30
Vanguard Small Cap Index 19793 0.02% 19793 -- 2019-06-30
Victory RS Small Cap Growth Eq VIP Ser 16900 0.01% 16900 -- 2019-06-30
GuideStone Funds Small Cap Equity Fund 11800 0.01% 11800 -- 2019-06-30
Victory RS Small Cap Equity Fund 11030 0.01% 11030 -- 2019-06-30
AMG Managers Special Equity Fund 10589 0.01% 10589 -- 2019-06-30
Vanguard Balanced Index Fund 695 -- 695 -- 2019-06-30
Undry FIL Global Focus Inst Pens 12 Life 377 -- 377 -- 2019-06-30
Undrly FIL Global Focus 4 Pen 377 -- 377 -- 2019-06-30
Vanguard Russell 2000 Growth Index Fund 307 -- 307 -- 2019-06-30
Vanguard US Equity Index Fund 216 -- 216 -- 2019-06-30
The Vanguard - Russell 2000 Grwth Idx CF 749 -- 749 -- 2019-06-30

James C. Momtazee Mr. James C. Momtazee is a Member & Head of Health Care at Kohlberg Kravis Roberts & Co. LP and a Member at KKR Management LLC. He is on the Board of Directors at HCA, Inc., Accellent LLC, and Arbor Pharmaceuticals, Inc. Mr. Momtazee was previously employed as a Principal by Donaldson, Lufkin & Jenrette Securities Corp. He also served on the board at PRA Health Sciences, Inc. and Lake Region Medical. Mr. Momtazee received his undergraduate degree from Stanford University and an MBA from the Stanford Graduate School of Business.
Charles J. Homcy Dr. Charles J. Homcy, MD, is an Independent Director at Global Blood Therapeutics, Inc., a Partner at Third Rock Ventures LLC, an Independent Director at Portola Pharmaceuticals, Inc. and a Scientific Advisor at Boston Millennia Partners. He is on the Board of Directors at Global Blood Therapeutics, Inc., CytomX Therapeutics Holdings LLC, Portola Pharmaceuticals, Inc., Ambys Medicines, Inc., Pliant Therapeutics, Inc. and The Johns Hopkins University. Dr. Homcy was previously employed as a Non-Employee Class II Director by MyoKardia, Inc., an Independent Director by Cephalon, Inc., a Clinical Professor by The University of California, San Francisco, a Director, Executive VP-Research & Development by COR Therapeutics, Inc., a Professor by Columbia University, a Clinical Professor by Presbyterian Hospital, Inc., a President-Medical Research Division by Lederle Laboratories, an Associate Professor by Harvard Medical School, a Principal by The General Hospital Corp., and a President-Medical Research by Wyeth Holdings LLC. He also served on the board at Geron Corp., Kosan Biosciences, Inc., Cytokinetics, Inc., Millennium Pharmaceuticals, Inc. and Topica Pharmaceuticals, Inc. He received his undergraduate degree from The Johns Hopkins University and a doctorate degree from The Johns Hopkins University.
Richard H. Scheller Dr. Richard H. Scheller is an Independent Director at Alector, Inc., an Independent Director at Xenon Pharmaceuticals, Inc., a Director & Chief Scientific Officer at Medrio, Inc., a Director, Chairman-Research & Development at BridgeBio Pharma, Inc., a Member at American Academy of Arts & Sciences and a Member at National Academy of Sciences. He is on the Board of Directors at Maze Therapeutics, Inc., Alector, Inc., BridgeBio Pharma LLC, DiCE Molecules, Inc., Xenon Pharmaceuticals, Inc., Oric Pharmaceuticals, Inc., Medrio, Inc., Cornerstone Pharmaceuticals, Inc., BridgeBio Pharma, Inc. and Fine Arts Museums of San Francisco. Dr. Scheller was previously employed as a Chief Science Officer & Head-Therapeutics by 23andMe, Inc., a Head-Genentech Research & Early Development by Roche Holding AG, an Executive VP-Research & Early Development by Genentech, Inc., and an Associate Professor by Stanford University. He also served on the board at Affinita Biotech, Inc. He received his undergraduate degree from the University of Wisconsin-Madison, a doctorate degree from Columbia University and a doctorate degree from California Institute of Technology.
Ali J. Satvat Mr. Ali J. Satvat is a Member at Kohlberg Kravis Roberts & Co. LP and a Member at KKR Management LLC. He is on the Board of Directors at Cohera Medical, Inc., Coherus BioSciences, Inc., PRA Health Sciences, Inc., Arbor Pharmaceuticals LLC and Healthcare Private Equity Association. Mr. Satvat was previously employed as a Principal by Apax Partners, Inc., a Principal by Audax Management Co. (NY) LLC, a Principal by Johnson & Johnson Development Corp., and a Principal by The Blackstone Group, Inc. He also served on the board at Chiron Holdings Pte Ltd. and The TriZetto Group, Inc. Mr. Satvat received his undergraduate degree from Harvard College and an MBA from The Wharton School of the University of Pennsylvania.
Eric I. Aguiar Dr. Eric I. Aguiar is Partner at Aisling Capital LLC, Independent Director at Invitae Corp., a Member at Council on Foreign Relations, Inc. and Member-Overseers Board at Tufts University School of Medicine. He is on the Board of Directors at Invitae Corp. Dr. Aguiar was previously employed as Non-Executive Director by Amarin Corp. Plc, Partner by Thomas, McNerney & Partners LLC, a Managing Director by HealthCare Ventures LLC, Chief Executive Officer & Director by Genovo, Inc., and Executive Director by TheraTech, Inc. He also served on the board at Amarin Pharmaceuticals, Inc., CardioKine, Inc., Intuity Medical, Inc., Locus Development, Inc., Metaphore Pharmaceuticals, Inc., Oriel Therapeutics, Inc., SkinMedica, Inc. and Virdante Pharmaceuticals, Inc. He received his undergraduate degree from Cornell University and a doctorate degree from Harvard Medical School.
Uma Sinha Dr. Uma Sinha is a Chief Scientific Officer at Eidos Therapeutics, Inc. and a Chief Scientific Officer at BridgeBio Pharma, Inc. Dr. Sinha was previously employed as a Chief Scientific Officer by Global Blood Therapeutics, Inc., a Vice President & Head-Biology by Portola Pharmaceuticals, Inc., a Principal by COR Therapeutics, Inc., a Principal by Genencor International, Inc., and a Senior Director-Cardiovascular by Takeda Oncology Co. She received her undergraduate degree from Presidency College and a doctorate degree from the University of Georgia.
Neil Kumar Dr. Neil Kumar is a Chief Executive Officer & Director at Eidos Therapeutics, Inc. and a Chief Executive Officer & Director at BridgeBio Pharma LLC. He is on the Board of Directors at Eidos Therapeutics, Inc., BridgeBio Pharma LLC and PellePharm, Inc. Dr. Kumar was previously employed as a Vice President-Business Development by MyoKardia, Inc., a Principal by Third Rock Ventures LLC, and an Associate Principal by McKinsey & Co., Inc. He received his undergraduate degree from Stanford University, a graduate degree from Stanford University and a doctorate degree from Massachusetts Institute of Technology.
Frank McCormick Frank McCormick founded BridgeBio Pharma, Inc. and BridgeBio Pharma LLC. He is on the board of PellePharm, Inc. and Chairman-Oncology at BridgeBio Pharma, Inc.
Michael Henderson Michael Henderson founded PellePharm, Inc. Presently, Dr. Henderson is SVP- Asset Acquisition, Strategy & Operations at BridgeBio Pharma, Inc.
Cameron Turtle Cameron Turtle is SVP-Portfolio Management & Development at BridgeBio Pharma, Inc. and Chief Business Officer of Eidos Therapeutics, Inc.
Brian C. Stephenson Brian C. Stephenson holds the position of Chief Financial Officer at BridgeBio Pharma, Inc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐